Abeona Therapeutics Inc. (ABEO) Shares Gap Up After Analyst Upgrade


Now have a look at past performance (weekly performance to year to date performance) how Abeona Therapeutics Inc. $22.43's average target is 15.92% above currents $19.35 stock price. Finally, Zacks Investment Research upgraded Abeona Therapeutics from a "hold" rating to a "buy" rating and set a $10.00 target price for the company in a report on Tuesday, July 11th.

Among 5 analysts covering Swiss Re (OTCMKTS:SSREY), 0 have Buy rating, 3 Sell and 2 Hold.

Abeona Therapeutics (NASDAQ:ABEO) last posted its quarterly earnings results on Tuesday, August 15th. The rating was maintained by Cantor Fitzgerald on Monday, May 15 with "Buy". Abeona Therapeutics (NASDAQ:ABEO)'s price sits 54.09% above from its 50-day moving average of $14.77 and 159.37% far from the stock's 200-day moving average which is $8.49. As per Tuesday, August 29, the company rating was maintained by Maxim Group. The stock of Abeona Therapeutics Inc (NASDAQ:ABEO) earned "Buy" rating by Cantor Fitzgerald on Tuesday, June 6. H.C. Wainwright maintained it with "Buy" rating and $20.0 target in Friday, September 8 report. The correct version of this story can be read at https://www.truebluetribune.com/2017/10/12/abeona-therapeutics-inc-abeo-earns-buy-rating-from-hc-wainwright-2.html.

W.W. Grainger, Inc.is a distributor of maintenance, fix and operating (MRO) supplies and other related services and products. The company has market cap of $32.16 billion. The Firm offers its services and products to businesses and institutions in the United States and Canada, with presence also in Europe, Asia and Latin America.

However looking at valuation ratios the stock has 5 year expected PEG ratio of 0 whereas its trailing twelve month P/E ratio is 0.

Ratings analysis reveals 33% of Grainger's analysts are positive. The rating was downgraded by Societe Generale on Thursday, September 1 to "Hold". The stock hit its twelve month high on 10/11/17, and twelve month low on 12/21/16.

Occulus Go Is A RM840 Standalone VR Headset
The display is a fast-switch LCD screen with a resolution of 2560x1440 pixels, and it comes with integrated headphones. Audi is one of Oculus For Business' launch partners and has been utilising Oculus Rift to build VR auto showrooms.

On 7/31/2015 Mark J Ahn, Director, bought 18,182 with an average share price of $5.50 per share and the total transaction amounting to $100,001.00. The rating was initiated by Jefferies with "Buy" on Friday, January 6. Coho Partners Ltd. owns 693,866 shares or 3.13% of their USA portfolio. (ABEO) most recent 13F filing, the company has 22 new institutional holders - accounting for 753,245 shares of its common stock. The Japan-based Mu Investments Co. Moreover, Evercore Wealth Mngmt Ltd Liability has 0.29% invested in AbbVie Inc (NYSE:ABBV) for 103,350 shares. Its share price has risen 46.56% in three months and is up 23.11% for the last five trades. W W Grainger Inc (GWW) has declined 21.15% since October 12, 2016 and is downtrending.

Analysts await W W Grainger Inc (NYSE:GWW) to report earnings on October, 17 before the open. They expect $1.37 EPS, up 13.22% or $0.16 from last year's $1.21 per share. Of those insider trades, 0 shares of Abeona Therapeutics Inc. were purchased and 0 shares were sold. The insider now holds 100,000 shares of Abeona Therapeutics Inc. It has outperformed by 134.32% the S&P500.

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases.

The company is now up by 14.55% percent from yesterday's close and is one of the top gainers in today's market. Checking in on some other ratios, the company has a Price to Cash Flow ratio of -39.135309, and a current Price to Earnings ratio of -30.800124. It is also developing ABO-201 (AAV CLN3) gene therapy for juvenile Batten disease (JBD); and ABO-301 (AAV FANCC) for Fanconi anemia (FA) disorder using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.